TNSN96100A1 - MELANGE D'ACIDES α - AMINES ET D'ACIDES BETA - AMINES, ET PROCEDE POUR AMELIORER LA TOLERANCE D'ACIDES BETA - AMINES ACTIFS D'UN POINT DE VUE PHARMACEUTIQUE - Google Patents

MELANGE D'ACIDES α - AMINES ET D'ACIDES BETA - AMINES, ET PROCEDE POUR AMELIORER LA TOLERANCE D'ACIDES BETA - AMINES ACTIFS D'UN POINT DE VUE PHARMACEUTIQUE

Info

Publication number
TNSN96100A1
TNSN96100A1 TNTNSN96100A TNSN96100A TNSN96100A1 TN SN96100 A1 TNSN96100 A1 TN SN96100A1 TN TNSN96100 A TNTNSN96100 A TN TNSN96100A TN SN96100 A TNSN96100 A TN SN96100A TN SN96100 A1 TNSN96100 A1 TN SN96100A1
Authority
TN
Tunisia
Prior art keywords
beta
amino acids
acids
tolerance
improving
Prior art date
Application number
TNTNSN96100A
Other languages
English (en)
Inventor
Michael Matzke Dr
Hans-Christian Milizer Dr
Joachim Mittendorf Dr
Franz Kunisch Dr
Axel Schmidt Dr
Wolfgang Schonfeld Dr
Karl Ziegelbauer Dr
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of TNSN96100A1 publication Critical patent/TNSN96100A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyrrole Compounds (AREA)

Abstract

LA PRESENTE INVENTION CONCERNE DES MELANGES D'ACIDES α -AMINES ET/OU DE LEURS DERIVES ET D'ACIDES CYCLOPENTANE- BETA -AMINES ET/OU DE LEURS DERIVES, DES PEPTIDES DES ACIDES α - AMINES ET DES ACIDES CYCLOPENTANE BETA - AMINES MENTIONNES CI-DESSUS, ET DES MELANGES CI-DESSUS ET DES PEPTIDES, QUI PRESENTENT UNE MEILLEURE TOLERANCE CHEZ LES ANIMAUX A SANG CHAUD, PAR COMPARAISON AVEC LES ACIDES CYCLOPENTANE BETA -AMINES PURS.
TNTNSN96100A 1995-07-19 1996-07-18 MELANGE D'ACIDES α - AMINES ET D'ACIDES BETA - AMINES, ET PROCEDE POUR AMELIORER LA TOLERANCE D'ACIDES BETA - AMINES ACTIFS D'UN POINT DE VUE PHARMACEUTIQUE TNSN96100A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19526274A DE19526274A1 (de) 1995-07-19 1995-07-19 Verbesserung der Verträglichkeit von pharmazeutisch wirksamen beta-Aminosäuren

Publications (1)

Publication Number Publication Date
TNSN96100A1 true TNSN96100A1 (fr) 2005-03-15

Family

ID=7767189

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN96100A TNSN96100A1 (fr) 1995-07-19 1996-07-18 MELANGE D'ACIDES α - AMINES ET D'ACIDES BETA - AMINES, ET PROCEDE POUR AMELIORER LA TOLERANCE D'ACIDES BETA - AMINES ACTIFS D'UN POINT DE VUE PHARMACEUTIQUE

Country Status (44)

Country Link
US (1) US5935988A (fr)
EP (2) EP0754678B1 (fr)
JP (2) JP3891503B2 (fr)
KR (1) KR100433968B1 (fr)
CN (1) CN1115145C (fr)
AR (1) AR003465A1 (fr)
AT (2) ATE198469T1 (fr)
AU (1) AU713555B2 (fr)
BG (1) BG62134B1 (fr)
BR (1) BR9603124A (fr)
CA (1) CA2181308A1 (fr)
CO (1) CO4700525A1 (fr)
CU (1) CU22820A3 (fr)
CZ (2) CZ287896B6 (fr)
DE (3) DE19526274A1 (fr)
DK (2) DK0754678T3 (fr)
DZ (1) DZ2073A1 (fr)
EE (1) EE03803B1 (fr)
ES (2) ES2275460T3 (fr)
GR (1) GR3035601T3 (fr)
HR (1) HRP960303B1 (fr)
HU (1) HUP9601977A3 (fr)
IL (1) IL118869A (fr)
MA (1) MA23940A1 (fr)
MX (1) MX9602836A (fr)
NO (1) NO315926B1 (fr)
NZ (1) NZ299008A (fr)
PE (1) PE9398A1 (fr)
PL (1) PL184861B1 (fr)
PT (2) PT1043332E (fr)
RO (1) RO118656B1 (fr)
RS (1) RS49520B (fr)
RU (1) RU2181123C2 (fr)
SA (1) SA96170491B1 (fr)
SG (1) SG47158A1 (fr)
SI (2) SI0754678T1 (fr)
SK (2) SK281850B6 (fr)
SV (1) SV1996000062A (fr)
TN (1) TNSN96100A1 (fr)
TR (1) TR199600583A2 (fr)
TW (1) TW496737B (fr)
UA (1) UA46725C2 (fr)
YU (1) YU20050685A (fr)
ZA (1) ZA966111B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191306B1 (en) * 1999-08-03 2001-02-20 Eastman Chemical Company Process for the preparation of cyclopropylglycine
KR20010073441A (ko) * 2000-01-14 2001-08-01 최인도 패류종묘 착상판의 제조방법
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
MXPA05012850A (es) * 2003-05-29 2006-05-17 New River Pharmaceuticals Inc Compuestos de anfetamina resistentes al abuso.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8716278D0 (en) * 1987-07-10 1987-08-19 Fujisawa Pharmaceutical Co Antimicrobial agent
JPH02174753A (ja) * 1988-08-25 1990-07-06 Fujisawa Pharmaceut Co Ltd シス―２―アミノシクロペンタンカルボン酸誘導体およびその製法ならびに抗菌剤
RU2030422C1 (ru) * 1990-04-27 1995-03-10 Фармацевтическое акционерное общество "Феррейн" Способ получения карнозина
AU673824B2 (en) * 1992-05-29 1996-11-28 Bayer Aktiengesellschaft Cyclopentane- and -pentene-beta-amino acids
DE4302155A1 (de) * 1993-01-27 1994-07-28 Bayer Ag Verwendung von Cyclopentan- und -penten-beta-Aminosäuren
US5631291A (en) * 1992-05-29 1997-05-20 Bayer Aktiengesellschaft Cyclopentane- and -pentene-β-amino acids
GB9216441D0 (en) * 1992-08-03 1992-09-16 Ici Plc Fungicidal process
WO1995007022A1 (fr) * 1993-09-07 1995-03-16 Zeneca Limited Fongicides
DE19548825C2 (de) * 1995-12-27 1999-03-25 Rolf Dr Hermann Neue, substituierte Cyclopentylaminderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE19604225A1 (de) * 1996-02-06 1997-08-07 Bayer Ag Stoffzusammensetzungen aus alpha-Aminosäuren und Cyclohexen-beta-aminosäuren

Also Published As

Publication number Publication date
EP1043332B1 (fr) 2006-11-02
DK0754678T3 (da) 2001-02-05
CO4700525A1 (es) 1998-12-29
YU20050685A (sh) 2006-08-17
ZA966111B (en) 1997-02-03
AU713555B2 (en) 1999-12-02
BR9603124A (pt) 1998-04-22
US5935988A (en) 1999-08-10
NO963000D0 (no) 1996-07-18
AU5948896A (en) 1997-01-23
CA2181308A1 (fr) 1997-01-20
PE9398A1 (es) 1998-04-15
MX9602836A (es) 1997-01-31
HRP960303A2 (en) 1998-02-28
DE59611398D1 (de) 2006-12-14
SA96170491B1 (ar) 2006-09-20
KR970006312A (ko) 1997-02-19
SV1996000062A (es) 1997-06-26
ATE198469T1 (de) 2001-01-15
HK1005131A1 (en) 1998-12-24
CZ214396A3 (en) 1997-02-12
CN1115145C (zh) 2003-07-23
EE03803B1 (et) 2002-08-15
JP3891503B2 (ja) 2007-03-14
SI0754678T1 (en) 2001-04-30
ATE344274T1 (de) 2006-11-15
RU2181123C2 (ru) 2002-04-10
SK94796A3 (en) 1997-02-05
IL118869A0 (en) 1996-10-31
JPH09202761A (ja) 1997-08-05
HUP9601977A2 (en) 1997-05-28
DK1043332T3 (da) 2007-03-12
TR199600583A2 (tr) 1997-02-21
PT754678E (pt) 2001-04-30
MA23940A1 (fr) 1997-04-01
ES2275460T3 (es) 2007-06-16
GR3035601T3 (en) 2001-06-29
UA46725C2 (uk) 2002-06-17
SG47158A1 (en) 1998-03-20
HRP960303B1 (en) 2001-08-31
YU41796A (sh) 1999-06-15
DE59606266D1 (de) 2001-02-08
AR003465A1 (es) 1998-08-05
IL118869A (en) 2002-03-10
NO963000L (no) 1997-01-20
DZ2073A1 (fr) 2002-07-22
RO118656B1 (ro) 2003-08-29
EP0754678A3 (fr) 1997-12-17
EP1043332A1 (fr) 2000-10-11
CZ287896B6 (cs) 2001-03-14
ES2154761T3 (es) 2001-04-16
CU22820A3 (es) 2003-01-29
EE9600109A (et) 1997-02-17
JP2007056026A (ja) 2007-03-08
CZ288204B6 (en) 2001-05-16
HUP9601977A3 (en) 1998-04-28
BG100716A (bg) 1997-04-30
KR100433968B1 (ko) 2004-08-30
BG62134B1 (bg) 1999-03-31
SK281850B6 (sk) 2001-08-06
SI1043332T1 (sl) 2007-04-30
NZ299008A (en) 1998-05-27
CN1143496A (zh) 1997-02-26
PL184861B1 (pl) 2003-01-31
PT1043332E (pt) 2007-01-31
RS49520B (sr) 2006-10-27
TW496737B (en) 2002-08-01
DE19526274A1 (de) 1997-01-23
EP0754678A2 (fr) 1997-01-22
PL315330A1 (en) 1997-01-20
EP0754678B1 (fr) 2001-01-03
NO315926B1 (no) 2003-11-17
SK284733B6 (sk) 2005-10-06
HU9601977D0 (en) 1996-09-30

Similar Documents

Publication Publication Date Title
EP0758843A4 (fr) Acides amines modifies en vue de l'administration de medicaments
TNSN95098A1 (fr) Derives de cycloalcanoindoles et de cycloalcanoaza-indoles
ATE211467T1 (de) 4-amino-derivate der mycophenolsäure mit immun suppressiver wirkung
TW264480B (fr)
ES2176286T3 (es) Esteres de metido de pentapeptidos inhibidoras del cancer de seres humanos.
TNSN96100A1 (fr) MELANGE D'ACIDES α - AMINES ET D'ACIDES BETA - AMINES, ET PROCEDE POUR AMELIORER LA TOLERANCE D'ACIDES BETA - AMINES ACTIFS D'UN POINT DE VUE PHARMACEUTIQUE
ATE210127T1 (de) 6-substituierte mycophenolsäurederivate mit immun suppressiver wirkung
EP0787009A4 (fr) Peptides inhibiteurs du cancer
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ES2141164T3 (es) Compuestos amfifilicos derivados de aminoacidos o de peptidos, sus metodos de sintesis y su aplicacion como sistemas de transporte de farmacos.
NZ276892A (en) Quinoxalinedione derivatives, preparation and use in pharmaceutical compositions thereof
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
DE69521055D1 (de) Spezifische peptid-wirksamkeit von anti-myelin basischem protein und die anwendung von myelin basischen protein-peptiden an multiple-sklerose-patienten
ES2075465T3 (es) Administracion de compuestos a animales acuaticos realizada mediante ultrasonidos.
DE69819110D1 (de) Ein Arzneimittel zur Behandlung von Fettleibigkeit und Verbesserung des lipidmetabolismus
NO893882D0 (no) Middel til forbedring av lipidmetabolisme og fremgangsmaate ved anvendelse derav.
PH31643A (en) 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease.
FR2711529B1 (fr) Composition à base d'acides aminés destinée au traitement d'une infection ou d'une agression engendrant une réaction inflammatoire, chez les animaux et chez l'homme.
DE69804302D1 (de) Kationische mittel zur transfektion von nukleinsäuren
DE69413637D1 (de) Verwendung von verzweigtkettigen Aminosäuren zur Herstellung eines Arzneimittels zur Behandlung von tardiver Dyskinesia
ATE210126T1 (de) 4-amino-6-substituierte mycophenolsäurederivate mit immunsuppressiver wirkung
IL105498A0 (en) Pharmaceutical composition containing ribonucleotide polymerase
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
ATE312179T1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
ATE165826T1 (de) 4-aminoderivate von 5-substituierten mycophenolsäuren